AIBN Annual Report 2013
Total Page:16
File Type:pdf, Size:1020Kb
AIBN Annual Report 2013 AIBN Annual Report 2013 Thank youAIBN Annual Report 2013 We thank our donors and benefactors for their continued generosity. AIBN’s research success has been enriched through ongoing philanthropic support and we remain grateful for the opportunities this provides. Vice-Chancellor’s message . 1 Wells Group: Facilities & research Web portal gains traction . 21 environment . 47 Director’s message . 2 Whittaker Group: Infrastructure facilitates research . 48 Board marks first full year . 3 Collaborations tackle diagnosis Research agreement for protein Scientific Advisory Committee . 4 and fabrication . 22 experts . 50 Wolvetang Group: Research highlights 2013 . 5 Disease models test regenerative medicines . 23 Alexandrov Group: Mentoring & career development . 51 Expression system gives Yu Group: protein insights . 6 Breakthrough technologies patented . 24 Commercial relevance part of PhD studies . 52 Bernhardt Group: Appointments . .25 Insight into nanomaterials from PhD first step to building a Theory and Computation . 7 Associate Group Leaders . 26 research career . 53 Cooper-White Group: ARC Fellowships . 28 Bridge between research and industry . 54 Researchers closer to clarifying Awards flow to AIBN . 29 stem cell clues . 8 Expertise and equipment aids career . 55 Funding . 30 Drennan Group: Graduate combines research Ceramic system stability explored . 9 and mentoring . 56 Gray Group: Commercialisation activities & Clinical trial closer for industry engagement . 31 Hendra virus therapy . 10 Engagement . 57 Suppressing anti-inflammatory drug Halley Group: side effects with nanomaterials . 32 Community engagement . 58 Polymer projects successfully TenasiTech nanoparticle additive School engagement . 59 finalised . 11 validated . 33 Sister city relationship builds Kendall Group: DSM scale-up facility opened . 34 knowledge . .60 Invention nears commercialisation . 12 Mahler Group: QSAFI completes significant work . 35 Cancer therapy in clinical trials . 13 Philanthropic initiative to support Student experience . 61 Martin Group: research . .36 RHD report . 62 Research converts Spinifex . 14 IAP links researchers with industry . 37 Graduates 2013 . 64 Middelberg Group: Internship brings industry relevance . 38 Advancing understanding of Student association builds biological interactions . 15 stronger community . 68 Monteiro Group: International collaborations . 39 Summer intake engages future Drug delivery mechanism fights Consortium exchanges valuable researchers . 69 cancer . 16 information . 40 Research higher degree students . 70 Nielsen Group: Merck, Vaxxas collaboration . 41 Complex system design and analysis . .17 Researchers’ bid for better batteries Trau Group: Grants & publications . 71 Grants advance rapid and reduced emissions . 42 Grants . 72 point-of-care diagnostics . 18 Point-of-care device gains momentum . 43 Publications . 74 Vinu Group: Dow partnership develops . 44 Research generates international Patents granted in 2013 . 82 collaborations . 19 ICBNI promotes in-depth collaborations . 45 Thank you . 84 Wang Group: Collaboration builds better batteries . 20 Queensland-China workshop . 46 Contact AIBN . 84 AIBN Annual Report 2013 1 Vice-Chancellor’s message t is my pleasure to offer some – Developing a prototype for diagnosing thoughts for this 2013 report gastrointestinal diseases, in concert with of the Australian Institute the Seattle Biomedical Research Institute for Bioengineering and and the University of Washington Nanotechnology, because much – Compiling data about the economic can be said about AIBN’s focus on competitiveness of biofuels – a developing tangible, sustainable component of a project involving Boeing, outcomes for society, the Virgin Australia, Mackay Sugar, IOR environment and economies. Energy, James Cook University and various UQ research units. AIBN continues to pursue excellence in As part of its future-proofing endeavours, research and forge connections that help AIBN has nurtured a growing number of it deliver impacts for the benefit of state, research higher degree students in recent national and global communities. years, with a record 27 doctors of philosophy With support from funding agencies, and masters of philosophy conferred in 2013. industry, collaborators, philanthropists, These UQ/AIBN alumni are vital not only the AIBN board and its Scientific Advisory for national and international knowledge Committee, AIBN people are pushing the leadership, but also for their future frontiers of science with a clear eye on the contributions to the productivity and practical implications of their work. prosperity of communities and corporations. In a determined quest for solutions to I strongly encourage these graduates, as knotty and expensive problems, they well as students currently linked to AIBN, are also pooling resources and expertise to value themselves as assets not only to with colleagues within UQ. These include academia and research, but also to industry researchers in some of UQ’s newest and society. They have the knowledge multidisciplinary entities, such as the Dow to help catalyse beneficial changes in Centre for Sustainable Engineering, and the industries that have far-reaching impacts. Solar Biofuels Research Centre. I thank all AIBN staff and partners, including Positive AIBN case studies are too numerous philanthropists, who are instrumental to to detail here, but examples include: positive AIBN outcomes. Please maintain – Working with Merck towards using the your keen focus on innovating to benefit Nanopatch to administer vaccines without people and the environment, because you the need for needles, syringes and will help establish the settings for sustainable refrigeration prosperity for many generations to come. – Collaborating with a new Chinese enterprise, Leling Shengli New Energy, and UQ’s School of Chemical Professor Peter Høj Engineering, which aims for better hybrid Vice-Chancellor and President car batteries The University of Queensland 2 AIBN Annual Report 2013 Director’s message The lifeblood of any vibrant research institute is its people and during 2013 our staff and students continued to excel in research excellence, impact and commercial vision. degree, completing an honours program and developments occurred with two ‘Premier’ publishing a seminal paper as lead author. members of the initiative. In October 2013 At the mid-career level, Associate Group DSM Biologics’ $65 million scale-up facility Leader Dr Simon Corrie was awarded for the Good Manufacturing Practice the 2013 Queensland Young Tall Poppy (GMP) standard production of biologics Science Award in recognition of his scientific was officially opened. These protein-based excellence towards developing new devices human therapeutics are made using DNA for medical diagnostics. technology, and now make up seven of the top 10 selling human therapeutics worldwide. At the senior level, we congratulate Professor Anton Middelberg, AIBN Group The opening was particularly significant for Leader and Deputy Director, who was me, as my involvement dates back to 2001 appointed as UQ’s Pro Vice-Chancellor when the Federal Government conducted Research and International, and Professor the Pharmaceutical Action Agenda that found Justin Cooper-White, Group Leader and a Australia should develop a national contract member of the AIBN executive, who was manufacturing organisation facility capable appointed a CSIRO Office of the Chief of GMP production of biologics for Australian Executive Science Leader. researchers and other global users. AIBN’s involvement in the project started about 10 It is particularly pleasing that our people not years ago, and it was particularly pleasing only contribute to UQ by providing high quality the DSM Biologics CEO, who launched and research, achieving more than 300 scholarly drove the project, said the presence of the publications in 2013, but more than 25 of strong base in biologics capability at AIBN our researchers actively contribute to the played a key role in the company’s decision university’s undergraduate and postgraduate to invest in Brisbane. coursework teaching programs. This is a key role we play in training the next generation of The year saw AIBN host its annual young scientists. conference overseas for the first time. We were delighted to accept a kind invitation Towards the end of the year, we were from Professor Bai Chunli, a member of delighted when Dr Zoe Cahill joined AIBN in AIBN’s Scientific Advisory Committee and ince moving into our custom-designed the pivotal role of Deputy Director (Operations). $76 million building in 2006, AIBN now President of the Chinese Academy has grown to an institute of 450 staff The year saw the ongoing success of our of Sciences, to hold the conference in and students with an annual turnover researchers in attracting competitive and Beijing. The conference, opened by Frances of $35 million. The high quality of the industry funding at national and international Adamson, Australian Ambassador to institute’s research was confirmed by levels. In what was a challenging year in China, was an outstanding success. It was the latest national Excellence in Research in Australia with reductions in research funding followed by visits to the National Centre for Australia exercise, which saw AIBN research at both state and federal levels, AIBN enjoyed Nanoscience and Technology, in Beijing; a ranked at 5, the highest ranking possible at continued success in national competitive workshop at Fudan University,